These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 24603328)

  • 1. Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors.
    Veschi V; Petroni M; Bartolazzi A; Altavista P; Dominici C; Capalbo C; Boldrini R; Castellano A; McDowell HP; Pizer B; Frati L; Screpanti I; Gulino A; Giannini G
    Cell Death Dis; 2014 Mar; 5(3):e1100. PubMed ID: 24603328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
    Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
    Shimada H; Nakagawa A; Peters J; Wang H; Wakamatsu PK; Lukens JN; Matthay KK; Siegel SE; Seeger RC
    Cancer; 2004 Oct; 101(8):1873-81. PubMed ID: 15386308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical expression of CD44s in human neuroblastic tumors: Moroccan experience and highlights on current data.
    Tabyaoui I; Tahiri-Jouti N; Serhier Z; Bennani-Othmani M; Sibai H; Itri M; Benchekroun S; Zamiati S
    Diagn Pathol; 2013 Feb; 8():39. PubMed ID: 23445749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinicopathologic features of peripheral neuroblastic tumors].
    Yang BF; Fu LB; He LJ
    Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):305-10. PubMed ID: 24004586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The deubiquitinating enzyme UCHL1 is a favorable prognostic marker in neuroblastoma as it promotes neuronal differentiation.
    Gu Y; Lv F; Xue M; Chen K; Cheng C; Ding X; Jin M; Xu G; Zhang Y; Wu Z; Zheng L; Wu Y
    J Exp Clin Cancer Res; 2018 Oct; 37(1):258. PubMed ID: 30359286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome prediction and risk assessment by quantitative pyrosequencing methylation analysis of the SFN gene in advanced stage, high-risk, neuroblastic tumor patients.
    Banelli B; Bonassi S; Casciano I; Mazzocco K; Di Vinci A; Scaruffi P; Brigati C; Allemanni G; Borzì L; Tonini GP; Romani M
    Int J Cancer; 2010 Feb; 126(3):656-68. PubMed ID: 19626586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential expression of delta-like gene and protein in neuroblastoma, ganglioneuroblastoma and ganglioneuroma.
    Hsiao CC; Huang CC; Sheen JM; Tai MH; Chen CM; Huang LL; Chuang JH
    Mod Pathol; 2005 May; 18(5):656-62. PubMed ID: 15605081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin D1 in pediatric neuroblastic tumors: A microarray analysis.
    Fagone P; Nicoletti F; Vecchio GM; Parenti R; Magro G
    Acta Histochem; 2015 Oct; 117(8):820-3. PubMed ID: 26510683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Correlation between typing of peripheral neuroblastic tumors and prognosis: a clinicopathologic study of 135 cases].
    YIN MZ; ZHANG ZD; MA J; SHEN P; CHEN JF; ZHANG HZ
    Zhonghua Bing Li Xue Za Zhi; 2011 Mar; 40(3):151-5. PubMed ID: 21575383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pathology of peripheral neuroblastic tumors].
    Wang L; He LJ; Shimada H
    Zhonghua Bing Li Xue Za Zhi; 2012 Apr; 41(4):283-8. PubMed ID: 22800533
    [No Abstract]   [Full Text] [Related]  

  • 12. Copy number gain of MYCN gene is a recurrent genetic aberration and favorable prognostic factor in Chinese pediatric neuroblastoma patients.
    Wang M; Zhou C; Cai R; Li Y; Gong L
    Diagn Pathol; 2013 Jan; 8():5. PubMed ID: 23320395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High incidence of MYCN amplification in a Moroccan series of neuroblastic tumors: comparison to current biological data.
    Tabyaoui I; Tahiri-Jouti N; Serhier Z; El Maani K; Cherkaoui S; Al Zemmouri M; Othmani MB; Zamiati S
    Diagn Mol Pathol; 2013 Jun; 22(2):112-8. PubMed ID: 23628823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Shimada H; Umehara S; Monobe Y; Hachitanda Y; Nakagawa A; Goto S; Gerbing RB; Stram DO; Lukens JN; Matthay KK
    Cancer; 2001 Nov; 92(9):2451-61. PubMed ID: 11745303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The International Neuroblastoma Pathology Classification (the Shimada system).
    Shimada H; Ambros IM; Dehner LP; Hata J; Joshi VV; Roald B; Stram DO; Gerbing RB; Lukens JN; Matthay KK; Castleberry RP
    Cancer; 1999 Jul; 86(2):364-72. PubMed ID: 10421273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytopathological spectrum of peripheral neuroblastic tumours in fine needle aspiration cytology and categorisation as per International Neuroblastoma Pathology Classification.
    Koshy A; Jain R; Srinivasan R; Bhatia P; Kakkar N; Rajwanshi A; Gupta N; Dey P; Trehan A; Bansal D
    Cytopathology; 2019 Nov; 30(6):634-643. PubMed ID: 31231909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG.
    Okamatsu C; London WB; Naranjo A; Hogarty MD; Gastier-Foster JM; Look AT; LaQuaglia M; Maris JM; Cohn SL; Matthay KK; Seeger RC; Saji T; Shimada H
    Pediatr Blood Cancer; 2009 Oct; 53(4):563-9. PubMed ID: 19530234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of cell proliferation in human neuroblastoma: comparison with other prognostic factors.
    Mejía C; Navarro S; Pellín A; Ruíz A; Castel V; Llombart-Bosch A
    Oncol Rep; 2003; 10(1):243-7. PubMed ID: 12469176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The RNA component of telomerase as a marker of biologic potential and clinical outcome in childhood neuroblastic tumors.
    Maitra A; Yashima K; Rathi A; Timmons CF; Rogers BB; Shay JW; Gazdar AF
    Cancer; 1999 Feb; 85(3):741-9. PubMed ID: 10091748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee.
    Suganuma R; Wang LL; Sano H; Naranjo A; London WB; Seeger RC; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Amann G; Beiske K; Cullinane CJ; d'Amore ES; Gambini C; Jarzembowski JA; Joshi VV; Navarro S; Peuchmaur M; Shimada H
    Pediatr Blood Cancer; 2013 Mar; 60(3):363-70. PubMed ID: 22744966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.